- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00790569
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
Varenicline Versus Nicotine Replacement for Methadone-Maintained Smokers
RATIONALE: Varenicline, the nicotine patch, and nicotine gum help people stop smoking. It is not yet known whether varenicline is more effective than the nicotine patch given together with nicotine gum in helping smokers quit smoking.
PURPOSE: This randomized clinical trial is studying varenicline to see how well it works compared with the nicotine patch given together with nicotine gum in helping smokers in a methadone treatment program stop smoking.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
OBJECTIVES:
Primary
- To determine whether varenicline, a nicotine receptor partial agonist, leads to a higher rate of smoking cessation than combination nicotine replacement therapy with nicotine patch prescription plus ad libitum nicotine gum delivery in methadone-maintained smokers.
Secondary
- To test the effects of the treatments on smoking urges, withdrawal symptoms, and reinforcing effects of smoking.
- To test the effects of the treatments on methadone treatment outcomes, including retention in methadone maintenance, methadone dose changes, and continued use of illicit drugs as measured by urine toxicologies.
OUTLINE: This is a multicenter study. Patients are stratified based on gender and level of nicotine dependence. Patients are randomized to 1 of 3 intervention arms.
At baseline, all patients receive a minimal behavioral intervention using a 3-minute, simple smoking cessation counseling strategy, a self-help manual, and a telephone quit-line number.
- Arm I (varenicline): Patients receive oral varenicline once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
- Arm II (placebo): Patients receive oral varenicline placebo once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
- Arm III (nicotine patch/gum): Patients receive a nicotine patch, with doses tapering over time for a total of 26 weeks. Patients also receive nicotine gum to quell breakthrough urges. Patients may stop treatment when a comfortable level of smoking abstinence is reached.
Patients complete a brief interview over 10-15 minutes at 2 weeks and monthly during months 1-5. They complete a longer interview over 45 minutes at months 6 and 12 and provide breath samples (for carbon monoxide monitoring) and urine samples (for cotinine testing).
NOTE: Smoking cessation may prevent certain smoking-related illnesses, including cancer.
PROJECTED ACCRUAL: A total of 602 patients (258 receiving varenicline, 258 receiving nicotine replacement therapy, and 86 receiving placebo) will be accrued for this study.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Rhode Island
-
Providence, Rhode Island, Estados Unidos, 02903
- Rhode Island Hospital Comprehensive Cancer Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
INCLUSION CRITERIA
- Current and regular cigarette smokers (over 10 cigarettes/day for the past 3 months)
Interested in quitting smoking
- Willing to set a quit date 7 days after baseline assessment
Participating in 1 of 5 methadone maintenance treatment programs across Rhode Island at any of the following institutions:
- Codac, Inc. (with two independent sites)
- Addiction Recovery Institute
- Center for Treatment and Recovery
- Discovery House
- Has received methadone for at least the past month
EXCLUSION CRITERIA
- Pregnant or nursing (Must have negative pregnancy test)
- Non-English speaking
- No personal telephone or does not live close to a relative or neighbor with a telephone
- Unwilling to make their methadone dose and methadone maintenance treatment program urine toxicologies available for review
- Unvailable for this study for the next 12 months
- Suffering from any unstable medical condition which would preclude the use of the nicotine patch (e.g., unstable angina or uncontrolled hypertension)
- Active skin condition (e.g., psoriasis)
- History of skin allergy
- History of a suicide attempt
- Working as pilots, drivers, or operators of heavy machinery
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No concurrent insulin or blood thinners
- No concurrent smokeless tobacco, nicotine replacement therapy, or other smoking cessation treatment
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Arm I
Patients receive oral varenicline once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
|
Given orally
|
Comparador de placebos: Arm II
Patients receive oral varenicline placebo once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
|
Administrado oralmente
|
Comparador activo: Arm III
Patients receive a nicotine patch, with doses tapering over time for a total of 26 weeks.
Patients also receive nicotine gum to quell breakthrough urges.
Patients may stop treatment when a comfortable level of smoking abstinence is reached.
|
Given transdermally and orally
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Self- Reported 7-day Abstinence
Periodo de tiempo: 6 Months
|
Number of participants with self-reported, 7-day abstinence at 6-months
|
6 Months
|
Carbon Monoxide (CO)-Confirmed 7-day Abstinence
Periodo de tiempo: 6-Months
|
Number of participants reporting 7-day abstinence at 6-months, confirmed with CO measurement.
|
6-Months
|
Rates of Smoking Cessation Continuous From First Quit Day to 6 Months
Periodo de tiempo: 6-Months
|
Number of participants who self-reported continuous abstinence from their initial quit day (study day 14) to 6 Months
|
6-Months
|
Self-reported 7-day Abstinence
Periodo de tiempo: 12 Months
|
Number of participants with self-reported 7-day abstinence at 12-months
|
12 Months
|
CO-confirmed 7-day Abstinence
Periodo de tiempo: 12 Months
|
Number of participants reporting 7-day abstinence at 12-months, confirmed with CO measurement.
|
12 Months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Change in Smoking Urges
Periodo de tiempo: 6 months
|
Smoking urges was measured on a 0 (not at all) - 100 (strongest feeling possible) scale.
Higher values represent greater urge to smoke.
Change in smoking urges was calculated as Follow-up score (6 month) - Baseline Score.
|
6 months
|
Withdrawal Symptoms
Periodo de tiempo: 6 months
|
Withdrawal Symptoms were measured using a modified version of the Minnesota Behavior Rating Scale.
The scale asked subjects to rate their smoking withdrawal symptoms over the previous 24 hours on a scale from 0 (none) to 4 (severe).
Higher values indicate more severe withdrawal symptoms.
Change in withdrawal symptoms was calculated as Follow-up score (6 month) - Baseline Score.
|
6 months
|
Retention in Methadone Maintenance
Periodo de tiempo: 12 months
|
12 months
|
|
Methadone Dose Changes
Periodo de tiempo: 12 months
|
12 months
|
|
Use of Illicit Drugs as Measured by Urine Toxicologies
Periodo de tiempo: 12 months
|
12 months
|
|
Reinforcing Effects of Smoking
Periodo de tiempo: 6 months
|
Reinforcing effects of smoking was measured using the modified version of the Cigarette Evaluation Questionnaire.
Participants were asked to indicate on a 12-item scale how smoking made them feel in the prior 30 days on a scale from 1 (Not at all) to 7 (Extremely).
Higher values indicated that smoking was a more positive experience for 10 of 12 items.
Two items were reverse coded.
Change in reinforcing effects of smoking was calculated as Follow-up score (6 month) - Baseline Score.
|
6 months
|
Change in Cigarettes Per Day
Periodo de tiempo: 6-Months
|
Change in mean cigarettes per day
|
6-Months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Silla de estudio: Michael Stein, MD, Butler Hospital
Publicaciones y enlaces útiles
Publicaciones Generales
- Stein MD, Caviness CM, Kurth ME, Audet D, Olson J, Anderson BJ. Varenicline for smoking cessation among methadone-maintained smokers: a randomized clinical trial. Drug Alcohol Depend. 2013 Dec 1;133(2):486-93. doi: 10.1016/j.drugalcdep.2013.07.005. Epub 2013 Aug 14.
- de Dios MA, Anderson BJ, Caviness CM, Stein M. Intimate partner violence among individuals in methadone maintenance treatment. Subst Abus. 2014;35(2):190-3. doi: 10.1080/08897077.2013.835764.
- Caviness CM, Bird JL, Anderson BJ, Abrantes AM, Stein MD. Minimum recommended physical activity, and perceived barriers and benefits of exercise in methadone maintained persons. J Subst Abuse Treat. 2013 Apr;44(4):457-62. doi: 10.1016/j.jsat.2012.10.002. Epub 2012 Nov 28.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
- cáncer de pulmón de células no pequeñas
- cáncer de esófago
- cáncer de vejiga
- cáncer gástrico
- Cancer de pancreas
- Carcinoma de células renales
- cáncer de pulmón de células pequeñas
- cáncer de cuello uterino
- cáncer orofaríngeo
- cáncer de laringe
- cáncer de hipofaringe
- cáncer primario de hígado en adultos
- cáncer de labio y cavidad oral
- cáncer de nasofaringe
- cáncer de seno paranasal y cavidad nasal
- leucemia mieloide aguda del adulto
- trastorno por consumo de tabaco
Términos MeSH relevantes adicionales
- Desordenes mentales
- Trastornos inducidos químicamente
- Enfermedades del Sistema Digestivo
- Trastornos relacionados con sustancias
- Enfermedades de las vías respiratorias
- Neoplasias
- Enfermedades pulmonares
- Neoplasias Urológicas
- Neoplasias urogenitales
- Neoplasias por sitio
- Enfermedades urológicas
- Enfermedades de la vejiga urinaria
- Neoplasias Uterinas
- Neoplasias Genitales Femeninas
- Enfermedades del cuello uterino
- Enfermedades uterinas
- Enfermedades del sistema endocrino
- Neoplasias Gastrointestinales
- Neoplasias del Sistema Digestivo
- Enfermedades Gastrointestinales
- Enfermedades del Estómago
- Neoplasias de glándulas endocrinas
- Enfermedades del HIGADO
- Neoplasias de las vías respiratorias
- Neoplasias torácicas
- Neoplasias de Cabeza y Cuello
- Enfermedades esofágicas
- Enfermedades pancreáticas
- Neoplasias del cuello uterino
- Neoplasias de Estómago
- Neoplasias Pulmonares
- Trastorno por consumo de tabaco
- Neoplasias de la vejiga urinaria
- Neoplasias pancreáticas
- Neoplasias Hepaticas
- Neoplasias Esofágicas
- Efectos fisiológicos de las drogas
- Agentes neurotransmisores
- Mecanismos moleculares de acción farmacológica
- Agentes Autonómicos
- Agentes del sistema nervioso periférico
- Agentes colinérgicos
- Estimulantes ganglionares
- Agonistas nicotínicos
- Agonistas colinérgicos
- Nicotina
- Vareniclina
Otros números de identificación del estudio
- CDR0000616663
- R01CA129226 (Subvención/contrato del NIH de EE. UU.)
- BUTLER-0807-004
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cancer de RIÑON
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos
-
Rabin Medical CenterReclutamiento